Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has entered into a licensing agreement with AstraZeneca UK (AstraZeneca) to introduce certain novel ready-to-use (RTU) infusion oncology products in China. The agreement will help to bring cost - effective and quality drugs to patients in China.

As per the terms of the agreement, the company will be responsible for development, regulatory filings and manufacturing the products covered in the agreement while AstraZeneca will exclusively promote and distribute these products in China. The initial tenure of the agreement is 10 years from the first commercial sale of the said products in China. The financial terms of the agreement are confidential. 

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.